Department of Physiology & Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Department of Nephrology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Oxid Med Cell Longev. 2020 Mar 26;2020:1609638. doi: 10.1155/2020/1609638. eCollection 2020.
Treatment for acute kidney injury (AKI) is challenging. Induced pluripotent stem cells (iPSCs) have great therapeutic potential. This study sought to determine whether iPSCs attenuate AKI and the role of reactive oxygen species (ROS).
We intravenously injected isogenic iPSCs into mice 2 h after renal ischemia-reperfusion injury (IRI). The cells were selectively trafficked to ischemia/reperfusion-injured kidney where they decreased kidney ROS and inflammatory cytokines and improved kidney function and morphology. Pretreating the cells with ROS inhibitors before administration decreased iPSC engraftment and abolished the protective effect of iPSCs. In contrast, pretreating iPSCs with hydrogen peroxide increased iPSC engraftment and therapeutic effect. Although the intravenously administered iPSCs trafficked to the IRI kidney, the cells did not differentiate into proximal or distal tubular epithelial cells. , the capabilities of the iPSC-released substances to promote proliferation and decrease apoptosis of renal epithelial cells were increased by ROS pretreatment of iPSCs. Moreover, pretreatment of the iPSCs with ROS inhibitor had the opposite effect. Similarly, moderate concentrations of ROS increased while ROS inhibitors decreased iPSC mobility, adhesion to the extracellular matrix, and mitochondrial metabolism. . iPSCs decreased renal ischemia/reperfusion injury mainly through iPSC-released substances. The therapeutic effect, mitochondrial metabolism, mobility, and kidney trafficking of iPSCs were ROS dependent.
急性肾损伤 (AKI) 的治疗具有挑战性。诱导多能干细胞 (iPSC) 具有巨大的治疗潜力。本研究旨在确定 iPSC 是否能减轻 AKI 以及活性氧 (ROS) 的作用。
我们在肾缺血再灌注损伤 (IRI) 后 2 小时通过静脉注射同基因 iPSC 到小鼠体内。细胞选择性地迁移到缺血/再灌注损伤的肾脏,减少肾脏 ROS 和炎症细胞因子,改善肾功能和形态。在给予细胞前用 ROS 抑制剂预处理会减少 iPSC 移植并消除 iPSC 的保护作用。相比之下,用过氧化氢预处理 iPSC 会增加 iPSC 移植和治疗效果。尽管静脉内给予的 iPSC 迁移到 IRI 肾脏,但细胞没有分化为近端或远端肾小管上皮细胞。然而,iPSC 释放的物质促进肾上皮细胞增殖和减少细胞凋亡的能力通过 ROS 预处理 iPSC 而增强。此外,iPSC 的 ROS 抑制剂预处理具有相反的效果。同样,中度浓度的 ROS 增加,而 ROS 抑制剂减少 iPSC 的迁移、粘附到细胞外基质和线粒体代谢。因此,iPSC 主要通过 iPSC 释放的物质减少肾缺血/再灌注损伤。iPSC 的治疗效果、线粒体代谢、迁移和肾脏归巢依赖于 ROS。